Disease Area

polycystic ovary syndrome

Polycystic ovary syndrome affects 6–13% of reproductive-age women and is the most common endocrine disorder in this population, characterised by hyperandrogenaemia, ovulatory dysfunction, and polycystic ovarian morphology. Management is tailored to the primary concern, whether fertility, menstrual irregularity, or metabolic risk, using hormonal contraception, letrozole, and lifestyle intervention. Inositol supplementation and GLP-1 receptor agonist use are among the most active areas of clinical investigation.

Polycystic Ovary Syndrome
PCOS Rename to PMOS: Critics Cite Diagnostic, Therapeutic Concerns
A proposed renaming of Polycystic Ovary Syndrome (PCOS) to Polycystic Ovarian Metabolic Syndrome (PMOS) faces criticism regarding diagnostic clarity and therapeutic implications.
Get the full story
11 min read
Polycystic Ovary Syndrome
PMOS: Clinical Implications for Patient Management
Understanding the impact of PMOS on patient quality of life is essential for GPs and specialists to guide appropriate management strategies.
Get the full story
7 min read
Polycystic Ovary Syndrome
PMOS: Insulin Resistance Impacts Fertility and Pregnancy Outcomes
Insulin resistance is a key factor in Polycystic Ovary Syndrome (PMOS), affecting reproductive health and increasing pregnancy complications.
Get the full story
7 min read
Polycystic Ovary Syndrome
PCOS Linked to Increased All-Cause Mortality Risk in Women
Polycystic Ovary Syndrome (PCOS) is associated with a significantly elevated risk of all-cause mortality, particularly from cardiovascular disease and diabetes.
Get the full story
8 min read

Loading articles...